The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study


      Paraoxonase is a high-density-lipoprotein associated enzyme capable of hydrolyzing lipid peroxides, which has been suggested to contribute to atherosclerosis and coronary heart disease (CHD). We studied the Gln/Arg polymorphism affecting codon 192 of human paraoxonase (PON 192) to determine whether this polymorphism, which is associated with serum paraoxonase (PON) activity, represents a risk factor for myocardial infarction (MI). The PON 192 polymorphism was analysed in 642 male patients with myocardial infarction and 701 age-matched controls participating in the ECTIM Study (Etude Cas-Témoins de l'Infarctus du Myocarde). The frequency of the Gln allele was 0.69 in cases and 0.70 in controls (ns). The frequency of the PON 192/Arg allele in 405 MI patients who underwent coronary angiography was 0.295, 0.323 and 0.331, respectively in those with 1, 2 or 3 stenosed arteries (stenosis > 50%) (ns). The mean levels of several plasma lipids, lipoproteins and apolipoproteins were compared between the 3 PON genotypes and no difference was observed. The PON 192 polymorphism was unrelated to MI, the severity of coronary atherosclerosis and to plasma levels of several lipid variables.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Schmiegelow K.
        • Eiberg H.
        • Tsui L-C
        • et al.
        Linkage between the loci for cystic fibrosis and paraoxonase.
        Clin Genet. 1986; 29: 374
        • Smolen A
        • Eckerson HW
        • Gan KN
        • Hailat N
        • La Du BN
        Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase.
        Drug Metab Dispos. 1991; 30: 141
        • Humbert R
        • Adler DA
        • Disteche CM
        • Hassett C
        • Omiecinski CJ
        • Furlong CE
        The molecular basis of the human serum paraoxonase activity polymorphism.
        Nature Genet. 1993; 3: 73
        • Adkins S
        • Gan KN
        • Mody M
        • La Du BN
        Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191 for the respective A or B allozymes.
        Am J Hum Genet. 1993; 52: 598
        • Saha N
        • Roy AC
        • Teo SH
        • Tay JSH
        • Ratnam SS
        Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins.
        Clin Genet. 1991; 40: 277
        • Hegele RA
        • Brunt JH
        • Connelly PW
        A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate.
        Arterioscler Thromb Vasc Biol. 1995; 15: 89
        • Ruiz J
        • Blanché H
        • James RW
        • et al.
        Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.
        Lancet. 1995; 346: 869
        • Mackness MI
        • Arrol S
        • Abbot C
        • Durrington PN
        Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.
        Atherosclerosis. 1993; 104: 129
        • WHO MONICA Project Principal Investigators
        The World Health Organization MONICA project (MONItoring trends and determinants in CArdiovascular disease): a major international collaboration.
        J Clin Epidemiol. 1988; 41: 105
        • Parra HJ
        • Arveiler D
        • Evans AE
        • et al.
        A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease: the ECTIM Study.
        Arterioscler Thromb. 1992; 12: 701
        • McElveen J
        • Mackness MI
        • Colley CM
        • Peard T
        • Warner S
        • Walker CH
        Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction.
        Clin Chem. 1986; 32: 671
        • Mackness MI
        • Durrington PN
        Paraoxonase: another factor in NIDDM cardiovascular disease.
        Lancet. 1995; 346: 856